Study assessing mechanisms of resistance to almonertinib and characterize clinically patients with EGFR-mutant lung cancers who had next-generation sequencing performed on tumor tissue or plasma after developing acquired resistance to almonertinib
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Aumolertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Oct 2022 New trial record
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress